Ziopharm: study supports development of ZIO-101 as cancer treatment

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Ziopharm Oncology, Inc. said data from a phase 1 study continues to support accelerated development of it novel organic arsenic, ZIO-101, in diverse cancers, including acute myelogenous leukemia and myelodysplastic syndrome.

The New York-based biopharmaceutical company presented the data at the Second European Society of Hematology Conference on Myeloproliferative Disorders in Madeira, Portugal.

Ziopharm is continuing to enroll subjects with diverse leukemias, lymphomas and other blood and bone marrow disorders in the trial. In addition, the company plans to expand its phase 2 development of the drug to include hematologic cancers and solid tumors.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.